A

Abbott India Ltd
NSE:ABBOTINDIA

Watchlist Manager
Abbott India Ltd
NSE:ABBOTINDIA
Watchlist
Price: 29 108.05 INR -0.99% Market Closed
Market Cap: 618.5B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ABBOTINDIA stock under the Base Case scenario is 23 526.63 INR. Compared to the current market price of 29 108.05 INR, Abbott India Ltd is Overvalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ABBOTINDIA Relative Value
Base Case
23 526.63 INR
Overvaluation 19%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

9.9
P/S
P/S
Price to Sales
9.9
vs History
30
vs Industry
13
Median 3Y
9.7
Median 5Y
8.6
Industry
2.4
Forward
9.4
More Details
46.4
P/E
P/E
Price to Earnings
46.4
vs History
79
vs Industry
8
Median 3Y
48.5
Median 5Y
49
Industry
20.5
Forward
44.7
More Details
61.2
P/OCF
P/OCF
Price to OCF
61.2
vs History
6
vs Industry
6
Median 3Y
49.7
Median 5Y
49.7
Industry
15.4
More Details
67.9
P/FCFE
P/FCFE
Price to FCFE
67.9
vs History
6
vs Industry
7
Median 3Y
54.3
Median 5Y
54.9
Industry
22.8
More Details
17.6
P/B
P/B
Price to Book Value
17.6
vs History
11
vs Industry
2
Median 3Y
15.8
Median 5Y
15.2
Industry
1.9
More Details
9.6
EV/S
EV/S
Enterprise Value to Sales
9.6
vs History
26
vs Industry
13
Median 3Y
9.4
Median 5Y
8.2
Industry
2.5
Forward
9.1
More Details
21.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
21.5
vs History
26
vs Industry
9
Median 3Y
20.9
Median 5Y
18.5
Industry
4.9
More Details
37.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
37.6
vs History
49
vs Industry
9
Median 3Y
38.3
Median 5Y
38.1
Industry
12.4
Forward
35.4
More Details
39.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
39.4
vs History
53
vs Industry
10
Median 3Y
40.4
Median 5Y
40.3
Industry
15.5
Forward
35.6
More Details
59.3
EV/OCF
EV/OCF
Enterprise Value to OCF
59.3
vs History
6
vs Industry
7
Median 3Y
48.1
Median 5Y
47.7
Industry
14
More Details
62.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
62.1
vs History
6
vs Industry
7
Median 3Y
50.1
Median 5Y
49
Industry
17.9
More Details
27.8
EV/IC
EV/IC
Enterprise Value to IC
27.8
vs History
74
vs Industry
3
Median 3Y
28.6
Median 5Y
35.4
Industry
1.8
More Details

Multiples Across Competitors

ABBOTINDIA Competitors Multiples
Abbott India Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Abbott India Ltd
NSE:ABBOTINDIA
618.5B INR 9.9 46.4 37.6 39.4
US
Eli Lilly and Co
NYSE:LLY
689.8B USD 15.2 64.1 38 40.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
359.1B USD 4 25.3 12 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.3 18 11.9 13.6
CH
Roche Holding AG
SIX:ROG
193.7B CHF 3.3 16.8 9.5 11.3
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.9 16.8 10.2 13.1
UK
AstraZeneca PLC
LSE:AZN
155.3B GBP 3.7 28.3 125.4 191.5
US
Merck & Co Inc
NYSE:MRK
198.4B USD 3.1 11.4 7.9 9.2
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
US
Pfizer Inc
NYSE:PFE
123.3B USD 1.9 15.2 7.7 10.9
P/E Multiple
Earnings Growth PEG
IN
A
Abbott India Ltd
NSE:ABBOTINDIA
Average P/E: 26.9
46.4
13%
3.6
US
Eli Lilly and Co
NYSE:LLY
64.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
25.3
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18
19%
0.9
CH
Roche Holding AG
SIX:ROG
16.8
16%
1.1
CH
Novartis AG
SIX:NOVN
16.8
16%
1
UK
AstraZeneca PLC
LSE:AZN
28.3
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.2
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
A
Abbott India Ltd
NSE:ABBOTINDIA
Average EV/EBITDA: 396.9
37.6
14%
2.7
US
Eli Lilly and Co
NYSE:LLY
38
30%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
15%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
8%
1.2
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
125.4
9%
13.9
US
Merck & Co Inc
NYSE:MRK
7.9
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
3%
2.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
A
Abbott India Ltd
NSE:ABBOTINDIA
Average EV/EBIT: 1 699.8
39.4
16%
2.5
US
Eli Lilly and Co
NYSE:LLY
40.7
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.3
9%
1.3
CH
Novartis AG
SIX:NOVN
13.1
8%
1.6
UK
AstraZeneca PLC
LSE:AZN
191.5
21%
9.1
US
Merck & Co Inc
NYSE:MRK
9.2
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1

See Also

Summary
ABBOTINDIA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ABBOTINDIA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ABBOTINDIA stock valuation using valuation multiples.
Wall Street Estimates
ABBOTINDIA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ABBOTINDIA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 245,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.